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Abstract
The purpose of this work is to evaluate biodegradable drug carriers with defined size, 
hydrophobicity, and surface charge density for preferential lymphatic uptake and retention for 
sustained regional drug delivery. PLGA–PMA:PLA-PEG (PP) nanoparticles of defined size and 
relative hydrophobicity were prepared by nanoprecipitation method. These were compared with 
PS particles of similar sizes and higher hydrophobicity. PLGA–PMA:PLGA-COOH (PC) particles 
at 80:20, 50:50, and 20:80 ratios were prepared by nanoprecipitation for the charge study. Particle 
size and zeta potential were characterized by dynamic light scattering and laser doppler 
anemometry, respectively. Particles were administered in vivo to rats subcutaneously. Systemic 
and lymph node uptake was evaluated by marker recovery. Lymphatic uptake and node retention 
of PP nanoparticles was shown to be inversely related to size. Lymphatic uptake and node 
retention of PP particles, as compared to PS particles, was shown to be inversely related to 
hydrophobicity. Lastly, lymphatic uptake and node retention of PC nanoparticles were directly 
related to the anionic charge on the particles. In vivo lymphatic uptake and retention in a rat model 
indicates that the 50 nm PP particles are ideal for sustained regional delivery into the lymphatics 
for prevention/treatment of oligometastases.
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INTRODUCTION
The lymphatic system is a uni-directional system closely associated with the circulatory 
system.1 The three main functions of the lymphatics are maintaining fluid balance, 
providing immune responses, and a specialized role in absorbing lipids in the 
gastrointestinal tract.2 While the lymphatics have been shown to be the target organ for 
disease states like HIV3 and lymphomas no commercial drug delivery systems exist to target 
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this region specifically. The lymphatics can also harbor metastatic cancer cells and is a 
region where oligometastases or nanometastases develop secondarily to the primary tumor 
cells.4 These oligometastases, are small numbers of cancerous cells localized to particular 
area, while nanometastases are small clusters of a few to several hundred tumor cells, which 
cannot be detected except by immunohistology of excised tissues. Both have the ability, 
overtime, to metastasize and spread the cancer to distal regions of the body.4,5 In such cases 
a regional therapeutic agent is required for preventative and therapeutic purposes.
Lymphatic drug delivery has been pursued by several workers.6–14 Key physicochemical 
parameters have been identified by these works as affecting lymphatic uptake. These 
parameters include molecular weight, size, charge, and hydrophobicity. Early studies using 
macromolecules and liposomes identified molecular weight and size as defining parameters 
for lymphatic uptake. Supersaxo.6 conclusively demonstrated that macromolecules with a 
molecular weight greater than 16 kDa have preferential lymphatic uptake. This finding was 
further supported by Takakura et al. in their studies with mitomycin conjugated to different 
molecular weight dextrans.7 Oussoren et al. demonstrated that subcutaneously (SC) injected 
small liposomes (~70 nm) had greater uptake into the lymphatics as compared to larger 
liposomes.8 Another parameter that has been shown to affect lymphatic uptake are the 
surface properties of the macromolecule or carrier system. Takakura et al. in their studies 
with mitomycin conjugated to different molecular weight cationic and anionic dextrans 
demonstrated that cationically charged conjugates were taken up to a lower degree as 
compared to neutral or anionically charged conjugates.9,10 Mohigimi et al. have shown that 
surface modification of 60 nm PS particles leads to differential lymphatic uptake patterns 
and lymph node retention.11 Similarly Hawley et al. have demonstrated sterically stabilized 
particles of polyethylene glycol coated 85 nm biodegradable polylactic-co-glycolic acid 
have differential lymphatic uptake and lymph node retention.12 Hydrophobicity, another 
parameter that can be tied to the surface properties of the particle can impact the uptake and 
retention of these particles by the lymphatic system.13 Hawley et al. have indirectly shown 
that as the hydrophobicity of the particle increases lymphatic uptake and lymph node 
retention decreases due to increased opsonization and phagocytosis of these particles.14
Despite the work done thus far no therapeutic products to treat the lymphatics regionally or 
in its entirety have emerged. This is probably due to the complexity of the interplay between 
the bulk properties of a carrier and its interaction with the lymphatic system itself. 
Additionally even though general trends have emerged from the body of literature in terms 
of size, charge, and hydrophobicity and lymphatic uptake there seems to be some variability 
between the different particulate systems. The other matter that must be considered for 
chronic lymphatic therapy is the long-term effect of the carrier/particulate system on the 
body. Clearly for any type of chronic therapy for regional or global purpose must include a 
biodegradable particulate system. A systemic study of properties of biodegradable polymeric 
drug carriers which can be modulated to successfully target the regional lymphatics is still 
lacking. Understanding the interplay of the bulk properties of biodegradable particles is 
crucial to developing a carrier system that can be utilized for chronic therapy. Thus the 
driving force for our research is to define the bulk properties, such as size, charge, and 
hydrophobicity, of a polymeric biodegradable drug carrier system which will be 
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preferentially taken up into the lymphatics and then be retained in the local lymph nodes for 
sustained regional drug delivery.
The purpose of this work is to evaluate the lymphatic uptake and node retention of 
biodegradable particles of varying sizes, hydrophobicity, and surface charge densities in vivo 
in rats. PLGA 50/50 was chosen as our polymer scaffold to fabricate the nanoparticles used 
in the study. The choice of PLGA was dictated by the fact that it can be used to form stable 
nanoparticles, has already been approved for use in humans by the FDA and is commercially 
available. PLGA was tracked in vivo by conjugating a marker molecule, PMA to the 
polymer backbone. This conjugate was coprecipitated with polyethylene glycol-co-
polylactic acid (PEG:PLA) at 75:25 ratios to make PP particles of 50, 100, and 200 nm for 
the size study. The reason for using PEG-PLA as a coprecipitant was to further lower the 
surface hydrophobicity of the nanoparticles. These particles were then compared with 
similarly sized, commercially available, non-biodegradable fluorescent PS particles for the 
hydrophobicity study. PS particles were chosen to compare with PLGA particles for the 
hydrophobicity study as PS particles are more hydrophobic compared to PLGA particles 
based on their water contact angle measurements [PLGA 50/50 is 76°15 and PS is 90°16]. It 
must be, however, kept in mind that there is no direct measure for hydrophobicity of 
particles and this study will provide only a qualitative comparison between PLGA and PS 
particles. For the charge study, PLGA–PMA 50 nm particles were prepared with varying 
charge densities by coprecipitating the conjugate with PLGA terminated with a carboxylic 
acid group (PC particles).
To evaluate different properties of a drug carrier leading to enhanced lymphatic uptake and 
regional lymph node retention nanoparticles of different sizes, hydrophobicities, and surface 
charges were used to ensure that only one of the three properties is being considered at one 
time in the context of the in vivo study. The effect of particle size was evaluated using PP 
nanoparticles of 50, 100, and 200 nm. The effect of hydrophobicity on lymphatic uptake and 
regional lymph node retention was evaluated by comparing the uptake and retention of PS 
60, 112, and 200 nm to PP 50, 100, and 200 nm, respectively. Lastly, the effect of surface 
charge density on lymphatic uptake and regional lymph node retention was evaluated by 
comparing the uptake and retention of 50 nm PC 80:20, 50:50, and 20:80 to each other and 
to the 50 nm PP particle.
MATERIALS AND METHODS
Materials
Poly(D,L-lactic-co-glycolic) acid (PLGA-COOH), acid end group 50/50 (inherent viscosity 
of 0.67) was purchased from Absorbable Polymers International (Pelham, AL). PMA 
hydrochloride, 95% pure, and diisopropylcarbodiimide (DIC), 99% pure were purchased 
from Sigma–Aldrich (St. Louis, MO). Poly(ethylene glycol-b-D,L-lactic acid) (PEG-b-PLA) 
was purchased from Polymer Source, Incorporated (Montreal, Canada). The molecular 
weights of the PEG and PLA blocks were 700 and 1800 g/mol, respectively. DIEA was 
acquired from Perspective Biosystems (Warrington, UK). Yellow green fluorescent PS 
particles of 60, 112, and 200 nm were purchased from Polysciences, Incorporated 
(Warrington, PA) and were diluted and used as received. Isoflurane (IsoFlo®) was ordered 
RAO et al. Page 3













from Abbott labs (Chicago, IL). Blood collection tubes (2 mL), containing 50 mM EDTA, 
were obtained from Midwest-Vet Supply (Madison, WI). Cellosolve acetate was purchased 
from Sigma, Inc. (St. Louis, MO). All other reagents were acquired from Fisher Scientific 
(Hanover Park, IL) and were of ACS grade.
Male wistar albino rats of approximately 300 g body weight were used in all experiments. 
The rats were obtained from Harlan (Madison, WI) and housed in the in-house animal care 
facility at School of Pharmacy, Madison, WI. The rats were maintained in a temperature and 
humidity controlled environment with free access to food and water. All procedures used in 
the study were approved by the research animal resources center (RARC) at University of 
Wisconsin, Madison, WI in compliance with the NIH principles of laboratory animal care.
Methods
Conjugation of PMA to PLGA—Conjugation of PMA to PLGA-COOH was done using 
standard amino acid reaction conditions.12,17–20 Briefly, PLGA-COOH 50:50 (5 g) was 
dissolved in 40 mL of dichloromethane (DCM). DIC was added in a 1:10 molar excess and 
the solution was stirred for 15 min to activate the terminal carboxylic group on the PLGA-
COOH. A 10 M equivalent of PMA was dissolved in 2 mL of DCM using DIEA to 
neutralize the salt form. The PMA solution was added drop wise to the polymer solution 
with stirring and the reaction was allowed to continue overnight protected from light and 
moisture. Conjugation was confirmed using thin layer chromatography. The PMA bound 
polymer was recovered by concentrating the reaction mixture and precipitating the polymer 
bound dye with diethyl ether. This process was repeated five additional times to ensure 
removal of all unbound dye molecules. Final purification of the PLGA–PMA was performed 
by washing three times with 0.1 N HCl and care was taken to minimize the time of exposure 
to the acid. The polymer was freeze-dried and stored under dry conditions, protected from 
light at −20°C. The separation of unconjugated free-PMA from a mixture of PLGA–PMA 
conjugate was confirmed by GPC. The polymer conjugate was also further characterized 
by 1H and 13C NMR.
Nanoparticle Formation—Nanoparticles were prepared by a modified nanoprecipitation 
method.12 PP (75:25) was dissolved in acetone at a final concentration of 0.1% (w/v). To 
this equal volume of water was added and the acetone was allowed to evaporate with 
continuous stirring, protected from light. By varying the rate of addition of the aqueous 
phase to the polymer solution in acetone it was possible to form nanoparticles of different 
sizes. The PLGA–PMA:PLGA-COOH (PC) particles were formed identically with the rate 
of addition fixed to yield 50 nm particles. The ratios at which the PLGA–PMA was 
coprecipitated with PLGA-COOH are 80:20, 50:50, and 20:80 in order to give particles with 
varying charge distribution.
Dynamic Light Scattering (DLS)—Hydrodynamic diameters were determined by DLS 
using the NICOMP ZLS380 particle sizer (particle sizing systems, Santa Barbara, CA). 
Samples were prepared at a concentration of 0.1% (w/v) in DI water. Data were acquired to 
have at least 100 K counts in channel 1. The light scattering data were interpreted using 
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Gaussian analysis. All particle sizes are expressed as volume-weighted diameters. The 
results are expressed as a mean of 25 measurements ±SD.
Laser Doppler Anemometry (LDA)—A Malvern Zetasizer Nano (Malvern, UK) with a 
PS disposable capillary cell was used for LDA measurements. Samples were freshly 
prepared in water and sample of 25 μL were run at ambient room temperature. The results 
are expressed as a mean of three measurements ±SD.
Degradation Study—In vitro degradation of nanoparticles was characterized by 
simultaneously quantifying the rate of degradation of PLGA and tracking the presence of the 
dye in the degraded fragments by UV at 338 nm and FL with excitation at 338 nm and 
emission at 368 nm.21 The experiment was conducted by adding 0.2 mg (2 mL volume) of 
PP nanoparticles of 50, 100, and 200 nm to a dialysis cassette slide-a-lyzer® with a MWCO 
of 3500. The samples were incubated under sink conditions at 37°C and at pH 7.4. At 
specific time intervals over 7 days, 200 μL samples were withdrawn, frozen, freeze dried, 
and stored for analysis at −80°C. This volume was replaced with an equal amount of DI 
water. For analysis, samples were dissolved in 0.2 mL of THF and filtered through a 0.2 μm 
nylon filter. The samples were analyzed by GPC using an Agilent 1100 Series LC system 
equipped with a Shodex KF-804 column with THF as the mobile phase. A flow rate of 1 
mL/min was maintained at 40°C with an injection volume of 50 μL. Polymer fragments 
were monitored by the RI detector while the PMA was quantified using the UV detector at 
338 nm and FL detector (excitation at 338 nm) emission at 368 nm. All measurements were 
done in triplicate. Molecular weights were calculated using PS standards.
Design of Animal Experiments—Male wister rats of approximately 300 g were used in 
the study. All procedures used in the study were approved by the RARC at University of 
Wisconsin, Madison, WI in compliance with the NIH principles of laboratory animal care. 
The animal study was divided into three groups with each group containing 10 rats per time 
point. The first group was the size study group which was given PP 50 or 100, or 200 nm 
particles SC (n = 150). The second group was the hydrophobicity study group which was 
administered PS 60 or 112, or 200 nm particles SC (n = 150). The last group was the charge 
study group which was administered 50 nm PC 80:20, 50:50, or 20:80 particles SC (n = 
150). All rats were dosed with 100 μL of particles containing 0.1 mg polymer. The injection 
was administered into the dorsal surface of the rat FP under isoflurane anesthesia (Fig. 1). 
Following the injection at various time points (3, 6, 12, 24, and 48 h) 1 mL of blood was 
drawn via the jugular vein and the rats were euthanized. The FP, left popliteal (LPN), 
inguinal (LIgN), iliac (LIN), and renal (LRN) lymph nodes were excised (Fig. 1) and were 
washed in phosphate buffered saline and stored at −80°C for further analysis. The blood 
samples were centrifuged at 5000 rpm for 5 min and the serum was placed in the 
heparinized tubes and stored at −80°C for further analysis. Total blood volume was 
estimated at 7.5% body weight.22
Extraction of PLGA–PMA from Biological Samples and Analysis of PMA by 
HPLC—A volume equivalent to 500 μL of serum or each tissue sample was placed in 500 
μL of 10 M NaOH or 1 mL of 10 M NaOH, respectively. All samples were sonicated using a 
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Branson sonifier (Branson Ultrasonics Corporation, Danbury, CT) for 20 s at 50% 
amplitude. They were placed in a sand bath for 2 h to allow tissue and polymer to degrade.23 
Samples were vortexed, split into four 1.8 mL centrifuge tubes and washed twice with 
chloroform. The washings were evaporated overnight in the dark and samples were 
reconstituted in 500 μL chloroform filtered through a 0.45 μm nylon filter and injected into a 
Econosil C18 10 μ column 250 mm × 4.6 mm (Alltech Associates, Inc., Deerfield, IL) 
connected to an Agilent 1100 Series LC system and a Fluorescence Monitor Model 1700 
(Bio-Rad Laboratories, Inc., Hercules, CA) FL detector. Samples were simultaneously 
detected by UV at 338 nm and by FL at 368 nm (excitation at 338 nm). The mobile phase 
was THF with a flow rate of 1 mL/min and an injection volume of 20 μL with a run time of 
8 min. The column temperature was maintained at 40°C. Detection limit for PMA by this 
method was 3.7 × 10−6 M with a retention time of 2.75 min. Recovery of marker from serum 
was ~85% and nodes ~80%.
Extraction of Fluorescent Marker in PS Particles from Biological Samples and 
Analysis of Marker by HPLC—A volume equivalent to 500 μL of serum or each tissue 
sample containing 500 μL of DI water were vortexed and sonicated using a Branson sonifier 
(Branson Ultrasonics Corporation) for 10 s each at 70% amplitude. A volume of 500 μL of 
cellosolve acetate was added and samples were vortexed and shaken at room temperature at 
250 rpm for 1 h to extract marker.24 The samples were then vortexed and centrifuged at 7000 
rpm for 5 min to sediment the PS. The supernatant was filtered through a 0.45 μm nylon 
filter and injected into a Econosil C18 10 μ column 250 mm × 4.6 mm (Alltech Associates, 
Inc.) connected to an Agilent 1100 Series LC system composed and a Fluorescence Monitor 
Model 1700 (Bio-Rad Laboratories, Inc.) FL detector. Samples were detected by FL at 480 
nm (excitation at 440 nm) with a marker retention time of 5.23 min. The mobile phase was 
an isocratic mixture of THF/water (60:40) with a flow rate of 1 mL/min and an injection 
volume of 20 μL with a run time of 7 min. The column temperature was maintained at 40°C. 
Recovery of marker from both serum and nodes was ~80%. In the case of these 
nanoparticles, the identity of the marker was not provided by the company and so a blank 
calibration curve of particles being treated under similar conditions was prepared in order to 
quantify the amount of particle uptake. Thus, no molar detection limit is available for this 
method.
Statistical Analysis—The statistical program GraphPad Prism 5 (Windows version 5, 
2008, GraphPad Software, Inc. San Diego, California) was used to analyze the data. The in 
vitro values were compared using one-way ANOVA at 5% significance level with Tukey’s 
multiple comparison test for postanalysis. Graph-Pad Prism 5 was also used to generate the 
pharmacokinetic parameter AUC needed in data analysis. Parameters obtained were 
compared using one-way ANOVA at 5% significance level with Tukey’s multiple 
comparison test for post-analysis or unpaired t-test at 5% significance level. To determine 
the number of animals included in the treatment groups, power analysis was performed with 
β set at 80% and α set at 5% level.
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Polymer Synthesis and Characterization
The conjugation of 1-PMA to PLGA 50:50 was confirmed by GPC and NMR. The parent 
PLGA-COOH 1H and 13C NMR spectra were acquired and the chemical shifts signals 
corresponded well with previously documented literature values.25–27 The polymer 
conjugate, PLGA–PMA 1H NMR spectrum showed all the characteristic peaks of the 
PLGA-COOH and the protons of the phenantherene ring system of the PMA in the range of 
7.8–8.4 ppm. Likewise, the 13C NMR spectrum of the PLGA–PMA, revealed signals from 
both the parent PLGA-COOH and PMA with the carbon atoms of the phenantherene ring 
system of PMA visible at 122–136 ppm.
Nanoparticle Characterization by DLS and LDA
The results for the nanoparticle characterization are listed in Table 1. Two sets of particle 
sizes were assessed: PP (75:25) particles for the size study and the PLGA–PMA:PLGA-
COOH (at ratios of 80:20, 50:50, and 20:80) (PC) for the charge study The PP particles for 
the size study were compared against each other using one-way ANOVA with Tukey’s 
multiple comparison postt-est. All three sizes of PP particles were statistically significantly 
different from each other indicating that any potential differences in uptake and retention in 
vivo can be attributed to size variation. Similarly the PC particles from the charge study 
were compared against the PP 50 nm particle using one-way ANOVA with Tukey’s multiple 
comparison posttest. The PC particles were compared against the 50 nm PP particle and the 
results indicate that the sizes were not statistically different. Therefore the potential 
differences in uptake and retention with these particles in vivo are not likely to be governed 
by size. The zeta potential values (ζ) for all particles have also been listed in Table 1. In 
general, the particles used in the charge study have lower ζ values (higher negative surface 
charge density) compared to the PP particles. The trend in the decreasing ζ values for charge 
particles follows increasing anionic charge density. Thus the 20: 80 PC particles had the 
lowest ζ values, followed by the 50:50, and then by the 80:20 PC particles. It is expected 
that this trend in surface charge differences will lead to differential in vivo uptake.
In Vitro Degradation of Nanoparticles
The in vitro degradation profiles for the 50, 100, and 200 nm PP particles at pH 7.4 in PBS 
over 7 days are given in Figure 2. As seen from the graphs, the FL and the UV signals from 
the PMA overlap the polymer degradation profile as detected by the RI detector. These 
results indicate that for all particle sizes the PMA remained associated with the bulk of the 
polymer as it degraded. The degradation profiles themselves are similar for all three particle 
sizes, with the overall trend for the nanoparticles degradation rate being PP 50 faster than PP 
100, which was in turn faster than PP 200 nm.
The premise for the in vitro degradation study was that the polymer rate of degradation 
would be faster than the rate of degradation of the amide bond connecting the dye to the 
polymer. It is therefore hypothesized that the majority of the dye would remain associated 
with the polymer until significant degradation of the polymer occurred. The in vitro 
degradation profiles for the 50, 100, and 200 nm PP particles indicate that for all particle 
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sizes the PMA stayed associated with the bulk of the polymer as it degraded (Fig. 2). 
Therefore, we could make the assumption that in vivo we were detecting the polymer–PMA 
conjugate and not the free-PMA. The degradation profiles themselves are similar for all 
three particle sizes, with the overall trend for the nanoparticle degradation being PP 50 faster 
than PP 100, which was faster than PP 200 nm. This trend is not surprising, as the 
degradation rate increases with decreasing size due to the higher surface area of the smaller 
particles. This rapid degradation for smaller particles is especially true in the initial phase of 
this biphasic degradation profile, which has been documented in literature.28 The initial 
rapid loss is thought to occur due to the compact structure of the polymer, which limits the 
diffusion of the degradation products, which in turn can auto catalyze the degradation 
process.29 The slower, latter, degradation is thought to occur due to the increased porosity of 
the particles leading to the loss of these degradative products, thus raising the internal pH, 
which in turn slows down the rate of ester hydrolysis.29
Animal Study
The results of the animal study will be discussed first from the view point of LPN (Fig. 1) 
accumulation as this is the primary node of interest and is the node being targeted for 
regional delivery into the lymphatics. Thereafter cumulative lymphatic uptake is discussed 
as this is the total amount recovered from all four nodes (LPN, LIgN, LIN, and LRN) (Fig. 
1). Lastly serum data for these particles will be presented. The marker, PMA alone was 
administered as a 100 μL dose of a 1 mg/mL solution into the dorsal surface of the rat FP as 
a negative control. Results indicated non-preferential lymph node uptake with significantly 
higher serum uptake as expected for a small molecule (data not shown).
Size Study
The results from the size study group treated with one of three PP particles, 50, 100, or 200 
nm are listed in Table 2 and Figure 3. Area under the curve (AUC0–48 h) data shows particle 
drainage from the injection site for all three particles with lymph node accumulation in all 
cases. Comparison of the three particle sizes of PP indicates a difference in the uptake and 
retention of these particles in the nodes. The drainage of PP 50 particles from the injection 
site was statistically significantly different until 6 h compared to PP 100 nm and PP 200 nm 
(data not shown). The rate of drainage from the injection site for all three particle sizes was 
statistically significantly different at the 3 h time point (data not shown).
The primary node of interest, LPN showed the greatest accumulation of all particles injected 
compared to the other nodes. The 50 nm particle has statistically significantly higher levels 
of the polymer for the first 6 h and at 48 h compared to the 100 and 200 nm particles (Fig. 
3). The uptake of the particles into LPN was size dependent with the highest uptake was for 
the smallest particles PP 50 AUC0–48 h 177.7 ± 8.7 followed by PP 100 AUC0–48 h 140.6 
± 8.7 and the lowest uptake was for the largest particles PP 200 at AUC0–48 h 94.5 ± 4.7 (mg 
h)/g (Tab. 2). The overall LPN accumulation of the 200 nm particle was significantly lower 
as compared to the 50 and 100 nm particles (Fig. 3). Comparison of the AUC values 
obtained from the LPN nodes shows a statistically significant trend in uptake and retention 
of PP particles in the regional node of interest (Fig. 3). Uptake in LIgN and LIN was similar 
within all particles groups. LRN had the least uptake of all particles, as it was the most distal 
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site assessed. Comparison of the cumulative nodal AUC shows the same trend and the 
primary contributor to the cumulative node uptake is the LPN. The order of uptake is PP 50 
then PP 100 followed by PP 200 particles.
Serum AUC0–48 h levels for PP 50, 100, and 200 are 6.29 ± 0.03, 5.30 ± 0.33, and 3.30 
± 0.24 (mg h)/mL, respectively (Tab. 4), which are statistically significantly different from 
each other. Serum levels for all three particle sizes tested indicate that the 50 nm particles 
have earlier accumulation into the vascular compartment than the 100 or 200 nm particles 
(Tab. 4). Over time, however, there is no difference in the serum levels for the 50 and 100 
nm particles. The 200 nm particles have the lowest serum accumulation and this becomes 
more pronounced at later time points (data not shown). Interestingly serum levels remain 
almost constant for the entire concentration time profile (data not shown). This indicates that 
the particles are probably not only accessing the vascular compartment through the thoracic 
lymph duct but also possibly through the lymphovenous communications present within the 
nodes. The serum uptake trend is similar to the node uptake with the order of serum 
accumulation being PP 50 then PP 100 followed by PP 200 particles.
Thus, the overall trend indicates that PP 50 particles have higher uptake and retention 
followed by PP 100 and then PP 200 particles. This is especially evident in the primary node 
levels, LPN, as seen in Table 2 and Figure 3. As the particle size increases, a lower amount 
of the particles traffic through the lymphatic system leading to lower accumulations in the 
nodes. When the concentration in the LPN is compared for all three sizes, they are all 
statistically significantly different from each other. This same trend is observed when 
looking at the overall nodal accumulation.
The size uptake study confirms previous studies done using liposomes and other carrier 
systems.30 Oussoren et al. have suggested that liposomal size is the most important factor 
that determines the extent of liposome absorption. Small, neutral liposomes less than 100 nm 
in size can be absorbed upto 70% by the lymphatics when administered SC. However, larger 
liposomes, greater than 100 nm, will remain at the injection site almost exclusively.30 Our 
results indicate that size is also the primary determinant for lymphatic uptake but for 
biodegradable nanoparticles some uptake of larger particles (>100 nm) is possible if the 
hydrophobicity of the particle can be altered.
Hydrophobicity Study
The results for uptake and distribution of the PS 60, 112, and 200 particles are listed in Table 
3. AUC0–48 h data shows particle drainage from the injection site for all three particles with 
lymph node accumulation in all cases (Fig. 4). Comparison of the PS particles used for the 
hydrophobicity study indicates a difference in the uptake and retention of these particles in 
the nodes (Tab. 3). The drainage of PS 60 particles from the injection site was not 
statistically significantly different from that of PS 112 particles (data not shown). This is 
probably due to the high hydrophobicity of the PS surface which leads to rapid aggregation 
at the injection site and thereby effectively increases the particle size of the 60 particle and 
makes it behave like the PS 112 particle. PS 200 nm particles however, having a much larger 
size are first limited by diffusion and then by the hydrophobicity which probably leads to 
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aggregation at the injection site. This in turns leads to statistically different drainage pattern 
for PS 200 particles when compared to the PS 60 or PS 112 particles (data not shown).
LPN, the primary node of interest, uptake and retention of PS particles was also different for 
the three particle sizes tested (Tab. 3 and Fig. 4). LPN showed the greatest accumulation of 
all particles injected compared to the other nodes. The uptake of the particles into LPN was 
size dependent with the highest uptake was for the smallest particles PS 60 AUC0–48 h 26.99 
± 4.53 followed by PS 112 AUC0–48 h 22.26 ± 2.71 and the lowest uptake was for the largest 
particles PS 200 at AUC0–48 h 3.67 ± 1.56 (mg h)/g (Tab. 3). However, the 60 nm particles 
do not have statistically significantly higher levels of the particles in the LPN as compared to 
the 112 nm particles. This is probably due to the hydrophobicity of these particles leading to 
rapid aggregation of the 60 nm particles before they can diffuse away. This makes the 60 nm 
particles behave like the 112 nm particles. In general, looking at the trend it seems like the 
60 nm particles do have a higher accumulation probably due to diffusion but this difference 
is not statistically significant. PS 200 nm particles had the lowest levels of nodal 
accumulation and were statistically significant at all time points when compared to the 60 or 
112 nm particles (Tab. 3 and Fig. 4). Comparison of the AUC values obtained from the LPN, 
regional node of interest, shows a decreasing trend in uptake and retention of PS particles in 
the order of PS 60 then PS 112 and then PS 200 (Tab. 3 and Fig. 4). Uptake into LIgN was 
only detected for the PS 60 particle. LIN uptake was lower than LPN uptake and no uptake 
was detected in LRN for all three particle groups. Comparison of the cumulative nodal AUC 
shows the same trend and the primary contributor to the cumulative node uptake is the LPN. 
The order of uptake is PS 60 then PS 112 followed by PS 200 particles, however there is no 
statistically significant difference between the PS 60 and PS 112 nm particles while both of 
these particles were statistically significantly higher than PS 200 particles.
Serum levels for all three particle sizes tested showed very low accumulation into the 
vascular compartment. Serum AUC0–48 h levels for PS 60, 112 were 0.056 ± 0.04, 0.097 
± 0.05 (mg h)/mL, respectively, while PS 200 particles were not detected in serum (Tab. 4). 
In the majority of the rats used for this study, serum levels remained low to undetectable 
(Tab. 4). PS 60 nm particles were the only particles that seemed to accumulate into the 
vascular compartment over time. However, the concentrations seen were statistically 
significant when compared to the 112 or the 200 nm particles (Tab. 4). The serum uptake 
trend is similar to the node uptake with the order of serum accumulation being PS 60 then 
PS 112 and then PS 200 particles.
Thus, the overall trend indicates that PS 60 particles have higher uptake and retention 
followed by PS 112 and then PS 200 nm particles. However, when the AUC for the overall 
nodal accumulation and specifically the LPN accumulation was compared, there was no 
statistically significant difference between the 60 and the 112 nm particles (Tab. 3). Both, 
however, are statistically significantly higher than the 200 nm particles. This is especially 
evident in the primary node levels (Tab. 3).
The comparative results from the hydrophobicity study of PS 60, PS 112, and PS 200 to PP 
50, PP 100, and PP 200, respectively, are listed in Table 4. When the LPN and overall nodal 
accumulation of PS particles are compared to PP particles (Tab. 4) it is obvious that PP (low 
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hydrophobicity) particles have much higher nodal accumulation than the PS (higher 
hydrophobicity) particles. These differences in accumulation are statistically significant for 
all three sizes. This is clearly indicative that hydrophobicity is the governing factor in the 
uptake of PS particles and not size. Looking at the serum concentration time profiles and 
comparing the two, it seems more likely that PS particles traffic almost entirely through the 
length of the lymphatic system and do not seem to traverse through the lymphovenous 
communications.
Charge Study
The charge density of 50 nm PC particles increases with increasing PLGA-COOH 
concentration with the 80:20 particles having the least anionic charge followed by the 50:50 
and then the 20:80 particles (Tab. 1). The comparative results from the charge study with the 
PC 80:20, PC 50:50, and PC 20:80 particles are listed in Table 5. AUC0–48 h data shows a 
differential particle drainage from the injection site for all three particles with lymph node 
accumulation in all cases. The rate of drainage from the injection site for PC 50:50 and PC 
80:20 particles, compared to PC 20:80 particles, remained statistically significantly lower 
for the first 24 h (data not shown). This is probably due to the higher charge density of the 
PC 20:80 particles which propels these particles from the interstitial spaces faster than the 
other two particle types. This differential movement through the interstitium is also seen, to 
a lesser degree, with PC 80:20 and PC 50:50. Thus, as the anionic charge density on the 
particle increases, it moves faster through the interstitium. This is because the interstitial 
matrix, under physiological conditions, carries a slight net negative charge.31 This charge 
repulsion probably accounts for differences in drainage patterns observed while size plays a 
minimal role as all the particles are 50 nm.
LPN uptake and retention of PC particles was also different for the three particle tested (Tab. 
5 and Fig. 5). These differences seen in the nodal uptake levels can be directly attributed to 
differences in surface charge density since the sizes for all three particles are similar (Tab. 
1). The uptake of the particles was charge density dependent into LPN with the highest 
uptake seen for PC 20:80 (most anionic) with an AUC0–48 h 187.00 ± 14.18 followed by PC 
50:50 AUC0–48 h 96.15 ± 1.72 and the lowest uptake was for the least anionic particles PC 
80:20 at AUC0–48 h 40.18 ± 5.27 (mg h)/g (Tab. 5). A statistically significant increase and 
retention in LPN of PC 20:80 particles were observed when compared to PC 50:50 particles 
and PC 80:20 particles. The accumulation of the PC 80:20 particles in the LPN remained the 
lowest for the entire duration of the study and is statistically significantly different for the 
first 24 h. Comparison of the AUC values obtained from the LPN, regional node of interest, 
shows a increasing trend in uptake and retention of PC particles in the order of PC 80:20, 
then PC 50:50, and then PC 20:80 (Tab. 5 and Fig. 5). Interestingly, the primary node of 
interest, LPN did not show the greatest accumulation of all particles injected compared to 
the other nodes. This is different from the PP and PS particles where size and 
hydrophobicity both resulted in maximal retention into the first set of regional lymph nodes. 
This difference might indicate that other uptake processes might be occurring 
simultaneously along with diffusion alone. We speculate that the anionic charge on these 
particles might trigger macrophage uptake and drainage into the regional lymph nodes is 
occurring both by diffusion and by intracellular transport with macrophages.
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Uptake in LIgN was detected for all the particles following the same trend as seen with LPN. 
LIgN AUC0–48 h values for PC 20:80, PC 50:50, and PC 80:20 are 302.90 ± 25.41, 97.85 
± 6.11, and 20.48 ± 1.96, respectively. LIN uptake was lower than LPN and LIgN uptake 
with the same trend. LIN AUC0–48 h values for PC 20:80, PC 50:50, and PC 80:20 are 72.18 
± 8.81, 34.63 ± 5.73, and 5.62 ± 0.71, respectively. LRN for all three particle groups was 
higher than LIN uptake, but mixed in comparison to LPN and LIgN uptake with the same 
trend for charge. LRN AUC0–48 h values for PC 20:80, PC 50:50, and PC 80:20 are 215.60 
± 28.31, 56.35 ± 4.75, and 11.05 ± 0.94, respectively. Comparison of the cumulative nodal 
AUC shows the same trend and LPN is not the primary contributor to the cumulative node 
uptake. As the surface charge density of the particles increases so do overall lymphatic 
uptake and lymph node retention, for any given set of particles, in the order of PC 80:20 
<PC 50:50 <PC 20:80 with statistically significant difference between all particles 
compared.
Serum AUC0–48 h levels for PC 80:20, PC 50:50, and PC 20:80 are 4.37 ± 0.48, 20.73 
± 1.62, and 68.93 ± 0.03 (mg h)/mL, respectively (Tab. 6). Serum accumulations for all PC 
particles were statistically significantly different from each other. The serum uptake trend is 
similar to the node uptake with the order of serum accumulation being PC 20:80 then PC 
50:50 and then PC 20:80 particles. As the anionic charge increases, an increasing number of 
the particles make it into the vascular compartment. Given the high concentrations present 
initially, we can once again consider that these particles are moving into the vascular system 
through the lymphovenous communications along with draining into the subclavian vein 
through the thoracic lymph duct. The PC 20:80 particles have significantly higher serum 
levels as compared to PC 50:50 which in turn are statistically significantly higher than PC 
80:20 particles. Another possibility for higher serum levels might be transport of these 
particles into the vascular compartment by macrophages.
Thus, the overall trend indicates that for similarly sized particles, as the anionic charge 
density increases, uptake into the lymphatic system also increases. Specifically, nodes distal 
to the injection site, and even the central vasculature, see much higher levels of these 
particles (Tab. 6). The LPN and overall nodal AUC values for the three particles were 
statistically significantly different from each other. This could be possibly due to faster 
trafficking of these particles from the injection site along with lower overall capture levels 
for these particles within the node. This idea is based on the fact that each node has a 
filtering capacity, which increases with increasing particle concentration until a unknown 
threshold value is reached, after which it decreases. Beyond this threshold value the particles 
will pass through the node and will be left to be filtered by subsequent nodes.31 Another 
possibility is that given these are negatively charged particles, macrophages are more active 
in transporting them into and through the lymphatic system.32 Thus, as the anionic charge 
increases so does the macrophage uptake. Unfortunately, due to the process by which these 
particles were recovered we were unable to determine which of these factors predominates.
Comparison of the PC particles with the PP 50 particles provides insight into the role of 
having a neutral PEG coated particles versus particles carrying anionic charges. Comparison 
of the PC particles with the neutral PP 50 particles (Tab. 6) shows a differential pattern in 
lymphatic uptake and node retention. Only the PC 20:80 particles, the highest anionic charge 
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density particles, have similar LPN retention as the PP 50 particles with AUC0–48 h of 187.0 
± 14.2 and 177.7 ± 8.7, respectively. Further comparison of the cumulative AUC ratios of 
the PC and PP 50 nm particles shows that the PC 80:20 particles primarily accumulate in the 
LPN. The other PC particles have statistically significantly lower LPN accumulation. This 
could be due to the fact that at lower ratios of PC particles the zeta potential for these 
particles is not much higher than for PP particles. However, the PP particles have an added 
shielding of a PEG coat which might prevent the aggregation of the PP particles, while the 
PC particles lacking this shield might aggregate at the injection site. Comparing individual 
node uptake for all the charge particles and PP 50 particles (Tabs. 2 and 5) indicates that 
charge particles distribute to a greater extent into the lymphatic system as compared to the 
neutral PP 50 particles. This difference in distribution might be indicative of decreased 
retention by the nodes due to the higher number of particles trafficking through them or due 
to a much higher macrophage involvement. The cumulative lymphatic uptake for PC 80:20 
particles was statistically significantly lower than PP 50 particles. The PC 50:50 particle 
uptake is statistically similar to the PP 50 particle with statistically significantly lower LPN 
levels. Lastly, the PC 20:80 particles have a statistically significantly higher cumulative 
lymph node uptake with similar LPN levels as the PP 50 particles (Tab. 6).
The work contained here leads to speculation regarding the role of macrophage uptake. 
Understanding the degree of macrophage involvement is critical to understanding the ability 
of the carrier to deliver the drug. Speculation has been made regarding the role of the PEG 
coating for the particles used in the size study in potentially evading macrophage uptake 
while the charged particles are expected to have extensive uptake. All of this inherently 
presupposes that different physicochemical properties of the carrier system will lead to 
different opsonin coatings,32 which in turn, will lead to differential macrophage uptake. 
Thus the next step is determining what these opsonin coatings are and if they are different 
for the different carriers. This is key to understanding how the carrier distributes within the 
lymphatics once they are taken up.
CONCLUSIONS
The lymphatic system is uniquely involved in several disease states and has been shown to 
be a site of metastasis for tumors. This work has shown that individual properties of size, 
hydrophobicity and surface charge density all play a significant role in the uptake of 
particles into the lymphatics for a biodegradable carrier system. We have been able to show 
that 50 nm PEG particles can work as a regional delivery system while the most anionically 
charged PC 20:80 particles might be better suited for systemic delivery with high lymphatic 
concentrations.
Based on our results, the best scaffold for drug delivery to the regional lymphatics might be 
through PEGylation of particles to provide some stealth like properties to these carriers, 
while maintaining a delicate balance between surface hydrophilicity and hydrophobicity. 
This is the same concept utilized in tethering drugs to macromolecules whilst achieving a 
delicate balance between size and hydrophobicity. This might allow for the localization of 
these particles into the regional lymph nodes. The 50 nm PLGA particles with a 
polyethyleneglycol coat have high primary node accumulation with low systemic levels and 
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lower lymphatic levels past the primary node. This type of a carrier system would be ideal 
for targeting the regional lymph nodes to prevent/treat oligometastases and nanometastases.
Acknowledgments
The authors would kindly like to acknowledge the contribution of Dr. Thomas Stringfellow for generously proving 
his expertise with NMR. They would also like to thank the School of Pharmacy, University of Wisconsin, Madison 
for funding.
Abbreviations





GPC gel permeation chromatography
HIV human immunodeficiency virus
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Schematic of the animal model (rat) depicting the site of injection and the nodes of interest.
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In vitro degradation profile of PP 50, 100, and 200 nm particles at pH 7.4, 37°C for 7 days 
(n = 3, mean ± SD).
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Comparative left popliteal node uptake (LPN) and retention for PP 50, PP 100, and PP 200 
particles from rat footpad; n = 10, mean ± SEM, *indicates statistical significance at a p-
value <0.05.
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Comparative left popliteal node uptake (lpn) and retention for PS 60, PS 112, and PS 200 
particles from rat footpad; n = 10, mean ± SEM, *indicates statistical significance at a p-
value <0.05.
RAO et al. Page 20














Comparative left popliteal node (LPN) uptake and retention for PC 80:20, PC 50:50, and PC 
20:80 particles from rat footpad; n = 10, mean ± SEM, *indicates statistical significance at a 
p-value <0.05.
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Table 1
Size and Zeta Potential of Particles as Assessed by DLS
Particles
Size
Mean ± SD (nm)
Zeta Potential
Mean ± SD (mv)
PP 50 56 ± 16.2* −36.1 ± 14.6
PP 100 109.3 ± 17.4* −34.2 ± 10.7
PP 200 201.8 ± 34.8* −35.5 ± 12.4
PC 80:20 50.0 ± 19.1 −44.6 ± 11.3
PC 50:50 50.2 ± 17.9 −48.0 ± 16.6
PC 20:80 46.9 ± 17.0 −57.1 ± 11.1
n = 25, mean ± SD (size) and n = 3 ± SD (ζ).
*
Denotes statistical significance at p < 0.05.
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